Article
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients
by
Mark R. Rigby;
Kristina M. Harris;
Ashley Pinckney;
Linda A. DiMeglio;
Marc S. Rendell;
Eric Felner;
Jean M. Dostou;
Stephen E. Gitelman;
Kurt J. Griffin;
Eva Tsalikian;
Peter A. Gottlieb;
Carla J. Greenbaum;
Nicole A. Sherry;
Wayne V. Moore;
Roshanak Monzavi;
Steven M. Willi;
Philip Raskin;
Lynette Keyes-Elstein;
S. Alice Long;
Sai Kanaparthi;
Noha Lim;
Deborah Phippard;
Carol L. Soppe;
Margret L. Fitzgibbon;
James McNamara;
Gerald T. Nepom;
Mario R. Ehlers;
T1DAL Study Group
2015